{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:13:44Z","timestamp":1792044824497,"version":"4.4.0"},"reference-count":282,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Analytical Chemistry"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/10408347.2025.2517357","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T06:47:17Z","timestamp":1750142837000},"page":"2119-2160","source":"Crossref","is-referenced-by-count":8,"title":["Risk Assessment, Detection and Control of Mutagenic Impurities in Pharmaceuticals: Emphasis on Nitrosamines"],"prefix":"10.1080","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7673-8229","authenticated-orcid":false,"given":"Aishwarya","family":"Dande","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)","place":["Hajipur, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Chandra Mouli","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshita","family":"Nandy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)","place":["Hajipur, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambhavi","family":"Shreya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Pallaprolu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)","place":["Hajipur, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gananadhamu","family":"Samanthula","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-637X","authenticated-orcid":false,"given":"Ramalingam","family":"P.","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)","place":["Hajipur, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105715"},{"key":"e_1_3_4_3_1","unstructured":"US FDA. M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk Guidance for Industry. 2018. https:\/\/database.ich.org\/sites\/default\/files\/M7_R1_Guideline.pdf (accessed Jan. 10 2025)."},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/op8002129"},{"key":"e_1_3_4_5_1","unstructured":"The European Medicines Agency in 2006. 2007. https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/summary-european-medicines-agencys-annual-report-2006_en.pdf (accessed Jan. 10 2025)."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1218-4"},{"key":"e_1_3_4_7_1","first-page":"87","article-title":"Genotoxicity: Damage to DNA and Its Consequences","volume":"99","author":"Phillips D. H.","year":"2009","unstructured":"Phillips, D. H.; Arlt, V. M. Genotoxicity: Damage to DNA and Its Consequences. EXS. 2009, 99, 87\u2013110.","journal-title":"EXS"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42764-021-00058-7"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2011.10.014"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aichem.2023.100011"},{"key":"e_1_3_4_11_1","unstructured":"USFDA. Information about Nitrosamine Impurities in Medications. 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/information-about-nitrosamine-impurities-medications (accessed Jan. 10 2025)."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2022.105245"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2020.1788375"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02120"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.12.022"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00153"},{"issue":"3","key":"e_1_3_4_17_1","first-page":"5","article-title":"Nitrosamine Drug Substance-Related Impurities (NDSRIs)","volume":"27","author":"Elder D.","year":"2022","unstructured":"Elder, D. Nitrosamine Drug Substance-Related Impurities (NDSRIs). Eur. Pharm. Rev. 2022, 27 (3), 5.","journal-title":"Eur. Pharm. Rev."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-024-00675-w"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.202400186"},{"key":"e_1_3_4_20_1","unstructured":"ICH Q3A (R2). Impurities in New Drug Substances Q3A(R2). 2006. https:\/\/database.ich.org\/sites\/default\/files\/Q3A%28R2%29%20Guideline.pdf (accessed Jan. 14 2025)."},{"key":"e_1_3_4_21_1","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline Impurities in New Drug Products Q3b(R2)","year":"2006","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline Impurities in New Drug Products Q3b(R2). 2006. https:\/\/database.ich.org\/sites\/default\/files\/Q3B%28R2%29%20Guideline.pdf (accessed Jan. 14, 2025)."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/em.22446"},{"key":"e_1_3_4_23_1","unstructured":"US FDA. Control of Nitrosamine Impurities in Human Drugs. 2021. https:\/\/www.fda.gov\/media\/141720\/download (accessed Jan. 14 2025)."},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/wcms.1475"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2018.04.014"},{"key":"e_1_3_4_26_1","unstructured":"OECD Guidelines for the Testing of Chemicals S. 4. Test No. 487: In Vitro Mammalian Cell Micronucleus Test; 2023. https:\/\/www.oecd.org\/en\/publications\/2023\/07\/test-no-487-in-vitro-mammalian-cell-micronucleus-test_g1g6fb2a.html (accessed Jan. 14 2025)."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/gead032"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/gead033"},{"key":"e_1_3_4_29_1","doi-asserted-by":"crossref","unstructured":"Teasdale A. Mutagenic Impurities: Strategies for Identification and Control; John Wiley & Sons: New York 2022.","DOI":"10.1002\/9781119551249"},{"key":"e_1_3_4_30_1","unstructured":"European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP) Guideline on the Limits of Genotoxic Impurities. 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-limits-genotoxic-impurities_en.pdf (accessed Jan. 10 2025)."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.1.2.187"},{"key":"e_1_3_4_32_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use S2(R1). 2011. https:\/\/database.ich.org\/sites\/default\/files\/S2_R1_Guideline.pdf (accessed Jan. 7 2025)."},{"key":"e_1_3_4_33_1","unstructured":"ICH M7(R2). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenicrisk M7(R2). 2023. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M7%28R2%29_Guideline_Step4_2023_0216_0.pdf (accessed Jan. 7 2025)."},{"key":"e_1_3_4_34_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Impurities: Guideline for Residual Solvents Q3C(R8). https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q3C-R8_Guideline_Step4_2021_0422_1.pdf (accessed Jan. 7 2025)."},{"key":"e_1_3_4_35_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Harmonised Guideline Guideline for Elemental Impurities Q3D(R1). https:\/\/database.ich.org\/sites\/default\/files\/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf (accessed Jan. 7 2025)."},{"key":"e_1_3_4_36_1","unstructured":"Federal register F. and D. A. Draft Guidance for Industry on Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches; Availability. 2008. https:\/\/www.federalregister.gov\/documents\/2008\/12\/16\/E8-29674\/draft-guidance-for-industry-on-genotoxic-and-carcinogenic-impurities-in-drug-substances-and-products (accessed Jan. 7 2025)."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2006.10.007"},{"key":"e_1_3_4_38_1","unstructured":"WHO. Update on Nitrosamine Impurities. 2019. https:\/\/www.who.int\/news\/item\/20-11-2019-information-note-nitrosamine-impurities (accessed Jan. 10 2025)."},{"key":"e_1_3_4_39_1","unstructured":"Department of Health and Aged Care A. G. Azide Impurity in \u201cSartan\u201d Blood Pressure Medicines. 2021. https:\/\/www.tga.gov.au\/news\/safety-alerts\/azide-impurity-sartan-blood-pressure-medicines#:\u223c:text=What%20is%20the%20azide%20impurity individual's%20risk%20of%20developing%20cancer (accessed Jan. 10 2025)."},{"key":"e_1_3_4_40_1","unstructured":"Liteplo R.; Meek M. E.; Windle W. N-Nitrosodimethylamine: First Draft; World Health Organization 2002. https:\/\/iris.who.int\/bitstream\/handle\/10665\/42422\/a73568.pdf (accessed Jan. 10 2025)."},{"key":"e_1_3_4_41_1","unstructured":"240911 USP-MHLW\/PMDA Joint WS. Past Present (& Future) Regulation on Nitrosamines in Japan. https:\/\/www.pmda.go.jp\/files\/000270830.pdf (accessed Jan. 10 2025)."},{"key":"e_1_3_4_42_1","unstructured":"USFDA. Control of Nitrosamine Impurities in Human Drugs Guidance for Industry Revision 2. 2024. https:\/\/www.fda.gov\/media\/141720\/download (accessed Jan. 10 2025)."},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-021-01822-1"},{"key":"e_1_3_4_44_1","unstructured":"USFDA. FDA Statement on the FDA\u2019s Ongoing Investigation into Valsartan and ARB Class Impurities and the Agency\u2019s Steps to Address the Root Causes of the Safety Issues. 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-fdas-ongoing-investigation-valsartan-and-arb-class-impurities-and-agencys-steps (accessed Jan. 14 2025)."},{"key":"e_1_3_4_45_1","unstructured":"US FDA. FDA Announces Voluntary Recall of Several Medicines Containing Valsartan Following Detection of an Impurity. 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity (accessed Jan. 14 2025)."},{"key":"e_1_3_4_46_1","unstructured":"US FDA. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan Losartan and Irbesartan). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan?utm_campaign=FDA%20updates%20on%20angiotensin%20II%20receptor%20blocker%20%28ARB%29%20recalls%3A%20ScieGen%E2%80%99s%20irbesartan%20recalled%20due&utm_medium=email (accessed Dec. 23 2024)."},{"key":"e_1_3_4_47_1","unstructured":"USFDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs. 2019. https:\/\/www.fda.gov\/media\/125478\/download (accessed Jan. 14 2025)."},{"key":"e_1_3_4_48_1","unstructured":"USFDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Ranitidine Drug Substance and Drug Product. 2019. https:\/\/www.fda.gov\/media\/130801\/download#:\u223c:text=This%20method%20will%20be%20used drug%20substance%20or%20drug%20product.&text=N%2Dnitroso%2Ddi%2Dmethylamine%20(NDMA)%20impurity%20is accuracy%20(HRAM)%20mass%20spectrometer (accessed Jan. 14 2025)."},{"key":"e_1_3_4_49_1","unstructured":"USFDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Metformin Drug Substance and Drug Product. 2020. https:\/\/www.fda.gov\/media\/134914\/download (accessed Jan. 14 2025)."},{"key":"e_1_3_4_50_1","unstructured":"US FDA. Recommended Acceptable Intake Limits for Nitrosamine Drug SubstanceRelated Impurities (NDSRIs) Guidance for Industry. 2023. https:\/\/www.fda.gov\/media\/170794\/download (accessed Jan. 14 2025)."},{"key":"e_1_3_4_51_1","unstructured":"US FDA. Updates on Possible Mitigation Strategies to Reduce the Risk of Nitrosamine Drug Substance-Related Impurities in Drug Products. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/updates-possible-mitigation-strategies-reduce-risk-nitrosamine-drug-substance-related-impurities (accessed Jan. 14 2025)."},{"key":"e_1_3_4_52_1","unstructured":"US FDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Varenicline Nitrosamine Drug Substance-Related Impurity (NDSRI) in Varenicline Drug Product and Drug Substance. 2024. https:\/\/www.fda.gov\/media\/175552\/download (accessed Jan. 15 2025)."},{"key":"e_1_3_4_53_1","unstructured":"European Medicines Agency (EMA). Assessment Report Procedure under Article 5(3) of Regulation EC (No) 726\/2004 Nitrosamine Impurities in Human Medicinal Products. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf (accessed Jan. 15 2025)."},{"key":"e_1_3_4_54_1","unstructured":"EMA. Questions and Answers for Marketing Authorisation Holders\/Applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 Referral on Nitrosamine Impurities in Human Medicinal Products. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf (accessed Jan. 15 2025)."},{"key":"e_1_3_4_55_1","unstructured":"EMA. Appendix 2 to Questions and Answers for Marketing Authorisation Holders\/Applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 Referral on Nitrosamine Impurities in Human Medicinal Products Carcinogenic Potency Categorisation Approach for Nnitrosamines. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-carcinogenic-potency-categorisation-approach-n-nitrosamines_en.pdf (accessed Jan. 15 2025)."},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13353-014-0198-9"},{"key":"e_1_3_4_57_1","first-page":"501","volume-title":"Biomaterials in Clinical Practice: Advances in Clinical Research and Medical Devices","author":"Cvetkovi\u0107 V. J.","year":"2017","unstructured":"Cvetkovi\u0107, V. J.; Taki\u0107 Miladinov, D.; Stojanovi\u0107, S. Genotoxicity and Mutagenicity Testing of Biomaterials. In Biomaterials in Clinical Practice: Advances in Clinical Research and Medical Devices; Springer: Cham, 2017; pp 501\u2013527."},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00015"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgv031"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2007.10.006"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0027-5107(00)00064-6"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800764-8.00004-5"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2019.07.004"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-023-03560-x"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2021.128010"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2024.503839"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-548-0_12"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0027-5107(00)00065-8"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-016-0044-x"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2022.124102"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.5603\/rpor.97433"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/app13042358"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109531"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-022-00754-y"},{"key":"e_1_3_4_75_1","first-page":"263","volume-title":"Immunohistochemistry and Immunocytochemistry: Methods and Protocols","author":"Dunkenberger L.","year":"2021","unstructured":"Dunkenberger, L.; Reiss, K.; Del Valle, L. Comet Assay for the Detection of Single and Double-Strand DNA Breaks. In Immunohistochemistry and Immunocytochemistry: Methods and Protocols; Springer: Cham, 2021; pp 263\u2013269."},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2023.503685"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxres\/tfaa093"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2022.864753"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/geab025"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2024.2384046"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.53730\/ijhs.v6nS7.12710"},{"key":"e_1_3_4_82_1","unstructured":"Halder S.; Narayana P. V. A Comprehensive Review of Current and Emerging Analytical Techniques for the Identification Quantification and Assessment of Genotoxic Impurities in Drug Substances. https:\/\/www.academia.edu\/figures\/11789470\/table-4-comprehensive-review-of-current-and-emerging"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/separations10030145"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2015.1111794"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12247-021-09607-9"},{"key":"e_1_3_4_86_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological\/Biological Entities) Q11. https:\/\/database.ich.org\/sites\/default\/files\/Q11%20Guideline.pdf (accessed Jan. 9 2025)."},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2005.12.001"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.0c00517"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.5b00091"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.06.009"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2007.10.013"},{"key":"e_1_3_4_92_1","unstructured":"International Agency for Research on Cancer (IARC). Monographs on the Identification of Carcinogenic Hazards to Humans. 2025. https:\/\/monographs.iarc.who.int\/agents-classified-by-the-iarc\/ (accessed Jan. 9 2025)."},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.11.023"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.03.054"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.0c02774"},{"key":"e_1_3_4_96_1","first-page":"381","volume-title":"Advances in Physical Organic Chemistry","author":"Williams D. L. H.","year":"1983","unstructured":"Williams, D. L. H. Nitrosation Mechanisms. In Advances in Physical Organic Chemistry; Elsevier: Amsterdam, 1983; Vol. 19, pp 381\u2013428."},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.03.022"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2023.12.009"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.027"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114872"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.0c00323"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfi169"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/separations8100162"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105355"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.4c00234"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.10.001"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00100"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.1c00162"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00199"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02523-w"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.028"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2022.12.010"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.04.021"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2023.121009"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jes.2022.05.024"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2022.116873"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2021.133363"},{"key":"e_1_3_4_118_1","unstructured":"N-Nitrosodimethylamine in Drinking-Water Background Document for Development of WHO Guidelines for Drinking-Water Quality. https:\/\/cdn.who.int\/media\/docs\/default-source\/wash-documents\/wash-chemicals\/ndma-2add-feb2008.pdf?sfvrsn=122aa3d3_4 (accessed Jan. 9 2025)."},{"key":"e_1_3_4_119_1","unstructured":"EPA (United States Environmental Protection Agency). Reference Dose (RfD): Description and Use in Health Risk Assessments Background Document 1A. 1993. https:\/\/www.epa.gov\/iris\/reference-dose-rfd-description-and-use-health-risk-assessments (accessed Jan. 9 2025)."},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114677"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121687"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-022-02491-7"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.07.014"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581809349195"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_60_20"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00274"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115066"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121740"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124832"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00404"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.06.013"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9747"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4927258"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-9351-2_21"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.08.010"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.13005\/bbra\/3272"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.03.005"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.3109\/10408448509029322"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16050647"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.2c00402"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c20-00431"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082015"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00118"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104749"},{"key":"e_1_3_4_145_1","unstructured":"Lhasa. Nitrites in Excipients Data Release: Supporting More Scientifically Driven Nitrosamine Risk Assessments. 2022. https:\/\/www.lhasalimited.org\/news\/nitrites-in-excipients-data-release-supporting-more-scientifically-driven-nitrosamine-risk-assessments\/"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpbao.2024.100034"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-99-1284-1_11"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06179"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2014.11.101"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.11.013"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673322023240829081220"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-025-03857-9"},{"key":"e_1_3_4_153_1","first-page":"247","volume-title":"Methods for Estimating Risk Ofchemical Injury: Human and Non-Human Biota and Ecosystems","author":"Purchase I. F. H.","year":"1985","unstructured":"Purchase, I. F. H. A Comparison of the Potency of the Mutagenic Effect of Chemicals in Short-Term Tests with Their Carcinogenic Effect in Rodent Carcinogenicity Experiments. In Methods for Estimating Risk Ofchemical Injury: Human and Non-Human Biota and Ecosystems. John Wiley: New York, 1985; pp 247\u2013269."},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1218(88)90017-1"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105672"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105730"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-024-03859-3"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c05170"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1002\/em.22618"},{"key":"e_1_3_4_160_1","unstructured":"European Directorate for the Quality of Medicines & HealthCare. Risk of the Presence of Mutagenic Azido Impurities in Losartan Active Substance. 2021. https:\/\/www.edqm.eu\/en\/-\/risk-of-the-presence-of-mutagenic-azido-impurities-in-losartan-active-substance (accessed Jan. 9 2025)."},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2023.104951"},{"key":"e_1_3_4_162_1","unstructured":"EMA. Valsartan: Review of Impurities Extended to Other Sartan Medicines. 2018. https:\/\/www.ema.europa.eu\/en\/news\/valsartan-review-impurities-extended-other-sartan-medicines (accessed Jan. 9 2025)."},{"key":"e_1_3_4_163_1","first-page":"1","article-title":"Analytical Strategies for Genotoxic Impurities in the Pharmaceutical Industry","volume":"17","author":"Venkatramani C. J.","year":"2014","unstructured":"Venkatramani, C. J.; Sayah, M. A. Analytical Strategies for Genotoxic Impurities in the Pharmaceutical Industry. Am. Pharm. Rev. 2014, 17, 1\u20135.","journal-title":"Am. Pharm. Rev."},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr300095f"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-153X-4-S1-S2"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2018.12.006"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/0887-2333(95)00040-f"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/0300-483x(95)03190-q"},{"key":"e_1_3_4_169_1","unstructured":"Toxtree - Toxic Hazard Estimation by Decision Tree Approach. https:\/\/toxtree.sourceforge.net https:\/\/toxtree.sourceforge.net\/ (accessed Jan 9 2025)."},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0273-2300(03)00071-0"},{"key":"e_1_3_4_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2013.05.001"},{"key":"e_1_3_4_172_1","doi-asserted-by":"publisher","DOI":"10.1080\/15376510701857379"},{"key":"e_1_3_4_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2013.09.015"},{"key":"e_1_3_4_174_1","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2280(2001)37:1<55::AID-EM1006>3.0.CO;2-5"},{"key":"e_1_3_4_175_1","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/17.4.321"},{"key":"e_1_3_4_176_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae303"},{"key":"e_1_3_4_177_1","unstructured":"Using ProTox. https:\/\/modrn.yale.edu\/education\/undergraduate-curriculum\/modrn-u-modules\/using-protox (accessed Jan. 10 2025)."},{"key":"e_1_3_4_178_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00217"},{"key":"e_1_3_4_179_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00380"},{"key":"e_1_3_4_180_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1415266"},{"key":"e_1_3_4_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105762"},{"key":"e_1_3_4_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104592"},{"key":"e_1_3_4_183_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2024.100300"},{"key":"e_1_3_4_184_1","unstructured":"HESI. Genetic Toxicology Technical Committee (GTTC). https:\/\/hesiglobal.org\/genetic-toxicology-gttc\/ (accessed Jan. 10 2025)."},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105403"},{"key":"e_1_3_4_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2003.08.006"},{"key":"e_1_3_4_187_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00008"},{"key":"e_1_3_4_188_1","doi-asserted-by":"publisher","DOI":"10.2478\/aiht-2021-72-3491"},{"key":"e_1_3_4_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2022.105247"},{"key":"e_1_3_4_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0278-6915(99)00024-1"},{"key":"e_1_3_4_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2022.02.005"},{"key":"e_1_3_4_192_1","doi-asserted-by":"publisher","DOI":"10.1021\/es5018009"},{"key":"e_1_3_4_193_1","doi-asserted-by":"publisher","DOI":"10.1002\/em.22615"},{"key":"e_1_3_4_194_1","doi-asserted-by":"publisher","DOI":"10.3109\/10715768709069795"},{"key":"e_1_3_4_195_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/16.1.89"},{"key":"e_1_3_4_196_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2001.tb01089.x"},{"key":"e_1_3_4_197_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1383-5718(03)00156-6"},{"key":"e_1_3_4_198_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2013.08.004"},{"key":"e_1_3_4_199_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470929377.ch11"},{"key":"e_1_3_4_200_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2017.10.027"},{"key":"e_1_3_4_201_1","first-page":"319","volume-title":"Pharmaceutical Industry Practices on Genotoxic Impurities","author":"Li J.","year":"2014","unstructured":"Li, J.; Wigman, L. Analytical Testing and Control for Genotoxic Impurities in Drug Substances. In Pharmaceutical Industry Practices on Genotoxic Impurities. Taylor and Francis Group: Boca Raton, FL, 2014; pp 319\u2013342."},{"key":"e_1_3_4_202_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.201401143"},{"key":"e_1_3_4_203_1","unstructured":"Wigman L.; Zhang K.; Kumar A. Analytical Technologies for Genotoxic Impurities in Pharmaceutical Compounds. 2015. https:\/\/www.chromatographyonline.com\/view\/analytical-technologies-genotoxic-impurities-pharmaceutical-compounds"},{"key":"e_1_3_4_204_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470929377.ch12"},{"key":"e_1_3_4_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2007.07.017"},{"key":"e_1_3_4_206_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.11.009"},{"key":"e_1_3_4_207_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2014.12.048"},{"key":"e_1_3_4_208_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2016.07.081"},{"key":"e_1_3_4_209_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.02.016"},{"key":"e_1_3_4_210_1","unstructured":"Yang H.; Moy E.; Volny M.; Martins C.; Du M.; Elmasri W.; Tadey T. Highly Sensitive and Robust LC-MS\/MS Solution for Quantitation of Nitrosamine Impurities in Metformin Drug Products. https:\/\/assets.thermofisher.com\/TFS-Assets\/CMD\/Application-Notes\/an-74059-lc-ms-nitrosamine-impurities-metformin-an74059-en.pdf"},{"key":"e_1_3_4_211_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00473-w"},{"key":"e_1_3_4_212_1","doi-asserted-by":"crossref","unstructured":"Wu Q.; Kvitko E.; Zenzola N.; Kucera K.; Light D. A Broadly Accessible Liquid Chromatography Method for Quantification of Six Nitrosamine Compounds and N N-Dimethylformamide in Metformin Drug Products Using High Resolution Mass Spectrometry. 2020. https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/60c751b29abda241b6f8dc84","DOI":"10.26434\/chemrxiv.13202849.v1"},{"key":"e_1_3_4_213_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113460"},{"key":"e_1_3_4_214_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113582"},{"key":"e_1_3_4_215_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.11.024"},{"key":"e_1_3_4_216_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008x(75)90256-2"},{"key":"e_1_3_4_217_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.0c00073"},{"key":"e_1_3_4_218_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.estlett.7b00059"},{"key":"e_1_3_4_219_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.6b03595"},{"key":"e_1_3_4_220_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2008.11.025"},{"key":"e_1_3_4_221_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.watres.2013.05.031"},{"key":"e_1_3_4_222_1","first-page":"1512","article-title":"A New Method for the Colorimetric Determination of Nitrosamines after Cleavage of the N-Nitroso-Group with Hydrogen Bromide in Glacial Acetic Acid","volume":"20","author":"Eisenbrand G.","year":"1970","unstructured":"Eisenbrand, G.; Preussmann, R. A New Method for the Colorimetric Determination of Nitrosamines after Cleavage of the N-Nitroso-Group with Hydrogen Bromide in Glacial Acetic Acid. Arzneimittelforschung 1970, 20, 1512\u20131517.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_4_223_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-9936(82)87008-8"},{"key":"e_1_3_4_224_1","doi-asserted-by":"publisher","DOI":"10.1021\/acssensors.4c00927"},{"key":"e_1_3_4_225_1","unstructured":"Yang J. F.; Marzan T.; Kakarla R.; Ye W.; Sommers C. (C.); Rodriguez J.; Keire D. LC-HRMS Based Analytical Platform to Determine Nitrosamines in Pharmaceuticals: Modern Analytical Techniques Meet Regulatory Needs. 2021. https:\/\/www.fda.gov\/science-research\/fda-science-forum\/lc-hrms-based-analytical-platform-determine-nitrosamines-pharmaceuticals-modern-analytical (accessed Jan. 10 2025)."},{"key":"e_1_3_4_226_1","doi-asserted-by":"crossref","unstructured":"James M.; Edge T. Low-Level Determination of Mutagenic Nitrosamine Impurities in Drug Substances by LC\u2013MS\/MS. 2021. https:\/\/www.chromatographyonline.com\/view\/low-level-determination-of-mutagenic-nitrosamine-impurities-in-drug-substances-by-lc-ms-ms","DOI":"10.56530\/lcgc.eu.dd3576s1"},{"key":"e_1_3_4_227_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2024.112439"},{"key":"e_1_3_4_228_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40543-020-00254-2"},{"key":"e_1_3_4_229_1","doi-asserted-by":"publisher","DOI":"10.1021\/jasms.4c00012"},{"key":"e_1_3_4_230_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2024.101495"},{"key":"e_1_3_4_231_1","unstructured":"USFDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of N-Nitroso-Bumetanide in Bumetanide Drug Products and Drug Substance. https:\/\/www.fda.gov\/media\/175550\/download"},{"key":"e_1_3_4_232_1","unstructured":"USFDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of N-Nitroso-Propranolol in Propranolol Hydrochloride Oral Solution. https:\/\/www.fda.gov\/media\/175550\/download (accessed Jan. 10 2025)."},{"key":"e_1_3_4_233_1","doi-asserted-by":"publisher","DOI":"10.9734\/ajacr\/2023\/v13i4251"},{"key":"e_1_3_4_234_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113671"},{"key":"e_1_3_4_235_1","unstructured":"Lee J. LC-MS\/MS Method for Detection and Quantitation of Azido Impurities in Irbesartan Drug Substance. Shimadzu Scientific Korea. https:\/\/www.shimadzu.com\/an\/sites\/shimadzu.com.an\/files\/pim\/pim_document_file\/applications\/application_note\/17021\/an_09-SSK-012-en.pdf (accessed Jan. 10 2025)."},{"key":"e_1_3_4_236_1","unstructured":"Berthelette K. D.; Nguyen J. M.; Trudeau M.; Turner J. E. Separation and Detection of an Azido Impurity in Sartan Drug Substances Using the XSelect CSH Phenyl-Hexyl Column by UHPLC-UV-MS. 2021. https:\/\/www.waters.com\/nextgen\/in\/en\/library\/application-notes\/2021\/separation-and-detection-of-an-azido-impurity-in-sartan-drug-substances-using-the-xselect-csh-phenyl-hexyl-column-by-uhplc-uv-ms.html?srsltid=AfmBOoqssQ1zqFIk6cyZQ-vdV_CFlNvoO2q3NTpB8nKMOmseCgfCnn0U (accessed Jan. 10 2025)."},{"key":"e_1_3_4_237_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116117"},{"key":"e_1_3_4_238_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.greeac.2023.100090"},{"key":"e_1_3_4_239_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3NJ05623F"},{"key":"e_1_3_4_240_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114612"},{"key":"e_1_3_4_241_1","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202400221"},{"key":"e_1_3_4_242_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.6025"},{"key":"e_1_3_4_243_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2024.465176"},{"key":"e_1_3_4_244_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmac059"},{"key":"e_1_3_4_245_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talo.2025.100416"},{"key":"e_1_3_4_246_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2024.140281"},{"key":"e_1_3_4_247_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202400277"},{"key":"e_1_3_4_248_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2025.465741"},{"key":"e_1_3_4_249_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9884"},{"key":"e_1_3_4_250_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpbao.2024.100027"},{"key":"e_1_3_4_251_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123593"},{"key":"e_1_3_4_252_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2023.464323"},{"key":"e_1_3_4_253_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2023.464416"},{"key":"e_1_3_4_254_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2024.465148"},{"key":"e_1_3_4_255_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113877"},{"key":"e_1_3_4_256_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.03.007"},{"key":"e_1_3_4_257_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121923"},{"key":"e_1_3_4_258_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114561"},{"key":"e_1_3_4_259_1","doi-asserted-by":"publisher","DOI":"10.1021\/es061332s"},{"key":"e_1_3_4_260_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.05.022"},{"key":"e_1_3_4_261_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.04.049"},{"key":"e_1_3_4_262_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114910"},{"key":"e_1_3_4_263_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcoa.2022.100053"},{"key":"e_1_3_4_264_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.watres.2007.07.022"},{"key":"e_1_3_4_265_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2022.107402"},{"key":"e_1_3_4_266_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lwt.2020.109716"},{"key":"e_1_3_4_267_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2016.02.048"},{"key":"e_1_3_4_268_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1001-0742(09)60281-3"},{"key":"e_1_3_4_269_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.watres.2011.06.041"},{"key":"e_1_3_4_270_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2022.132046"},{"key":"e_1_3_4_271_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2014.01.009"},{"key":"e_1_3_4_272_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talo.2024.100375"},{"key":"e_1_3_4_273_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2024.111678"},{"key":"e_1_3_4_274_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116459"},{"key":"e_1_3_4_275_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2024.124275"},{"key":"e_1_3_4_276_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40543-023-00378-1"},{"key":"e_1_3_4_277_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114630"},{"key":"e_1_3_4_278_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114974"},{"key":"e_1_3_4_279_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2022.06.010"},{"key":"e_1_3_4_280_1","doi-asserted-by":"publisher","DOI":"10.47750\/pnr.2022.13.S01.230"},{"key":"e_1_3_4_281_1","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.202100076"},{"key":"e_1_3_4_282_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116000"},{"key":"e_1_3_4_283_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2023.2276283"}],"container-title":["Critical Reviews in Analytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408347.2025.2517357","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10408347.2025.2517357","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408347.2025.2517357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:34:19Z","timestamp":1790660059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10408347.2025.2517357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":282,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/10408347.2025.2517357"],"URL":"https:\/\/doi.org\/10.1080\/10408347.2025.2517357","relation":{},"ISSN":["1040-8347","1547-6510"],"issn-type":[{"value":"1040-8347","type":"print"},{"value":"1547-6510","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}